Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694947 | 0.80 | DRD2 (0.64) | DRD2DRD4DRD3HTR1A | |
| SCHEMBL6701277 | 0.78 | DRD2 (0.66) | DRD2DRD4DRD3PARP2PARP1 | |
| SCHEMBL7253120 | 0.78 | NPC1 (0.51) | DRD2DRD4DRD3NPC1HTR7 | |
| SCHEMBL6701672 | 0.76 | DRD2 (0.46) | DRD2DRD4DRD3PARP2PARP1 | |
| SCHEMBL3968181 | 0.75 | DRD2 (0.73) | DRD2DRD4DRD3PARP2PARP1 | |
| SCHEMBL3121473 | 0.74 | NPC1 (0.60) | DRD2DRD4DRD3NPC1PARP1 | |
| SCHEMBL6968950 | 0.74 | NPC1 (0.60) | DRD2DRD4NPC1HTR7HTR1A | |
| SCHEMBL6961329 | 0.74 | NPC1 (0.60) | NPC1HTR7HTR1A | |
| SCHEMBL18046809 | 0.73 | DRD2 (0.49) | DRD2DRD4DRD3 | |
| SCHEMBL18046808 | 0.73 | DRD2 (0.49) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | DAUGAN ALAIN CLAUDE-MARIE (FR) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044008-A1 | Use of therapeutic benzamide derivatives | MTTP, LIPC, CETP | DRD2 4278/4885DRD4 4206/4885DRD3 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.